Description of Patients With Type 1 Diabetes Treated With Teplizumab

Launched by SANOFI · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called teplizumab for patients with Type 1 diabetes (T1D). Type 1 diabetes is a condition where the body mistakenly attacks the cells in the pancreas that produce insulin, leading to high blood sugar levels. Teplizumab has been found to help delay the progression of diabetes in patients who are in the earlier stages of the disease, specifically those who show certain autoantibodies but do not yet have severe symptoms. The trial aims to collect information about how teplizumab is used in everyday care and to learn more about the patients who receive this treatment.

To participate in the trial, individuals need to have received at least one day of teplizumab treatment and must provide consent. The trial is open to all ages and genders, and it allows for patients to be involved as long as they haven't joined another clinical study that changes standard treatment practices. Participants can expect to share their experiences with teplizumab and how it has affected their diabetes management, helping researchers gather valuable insights that could improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient informed consent or assent (for patients \< 18 years old) according to local regulations or appropriate informed consent waivers prior to any study related activity.
• • Patient received ≥ 1 day of teplizumab treatment.
• Exclusion Criteria:
• • Participation in an interventional clinical study on the index date. Participation in an interventional clinical study is defined as initiating the product/procedure or control under investigation. An interventional clinical study is a study that requires deviation from standard clinical practice by following a study protocol.